Aim:~Primary objective:~To evaluate the effect of continuing high dose clopidogrel treatment on adverse cardiac events after elective PCI in patients with clopidogrel resistance~Secondary objective:~To evaluate the effect of continuing high dose clopidogrel treatment on adverse cardiac events after elective PCI~To evaluate the effect of continuing high dose clopidogrel treatment on bleeding complications after elective PCI~To evaluate the clinical effect of VerifyNow which use as a clopidogrel resistance kit.~Study central:~Bursa Postgraduate Hospital, Cardiology Clinic~Study population:~we planned to enrol 180 patients. 50% of patients without clopidogrel resistance (control group: 90 patients) 50% have clopidogrel resistance. Than we randomise the patients (with clopidogrel resistance) in two groups (group 1:45 patients (75mg/day), group 2:45 patients (150mg/day))~inclusion criteria:~The patients; who have planned elective PCI and have had written informed consent for participation to study.~Age>18 year-old,~The native coronary artery;lesion with narrowing >=70%~Exclusion criteria:~Patients have allergy for ASA, Clopidogrel and heparin~Patients who performed primary PCI~Patients with acute coronary syndrome~Patients with have a history of PCI and use clopidogrel~Patients on warfarin therapy~Patients who have bleeding diathesis, or have high risk for bleeding.~Study works:~Write case report form for all patients~Control for inclusion criteria.~Evaluate the clopidogrel and ASA resistance with VerifyNow kit. Than randomised the patients.~Demographic data (age, gender)~Height, weight, BMI and GFR~Risk factors~laboratory data (biochemical and hematologic)~Medication history~Echocardiographic data~Angiographic data~PCI data(vessel diameter, stent diameter, lesion and stent length, performed PTCA or not, etc)~Note complication (MACE, bleeding, hematoma etc)~4 weeks later note the first control data and re assess the clopidogrel resistance with VerifyNow kit in patients groups 1 and 2.~Six months later note the second control data.
Continuing high dose clopidogrel treatment after elective PCI decreased adverse cardiac events in patients with clopidogrel resistance